The FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for pretreated, advanced squamous cell carcinoma of the anal canal based on phase 1/2 GOBLET trial ...

TG-C is a novel, off-the-shelf cell and gene therapy designed to slow OA progression and provide a non-surgical alternative to standard of care therapies.

For those ultimately able to fill the prescription, study revealed treatment was delayed by 12 days on average.

A new pilot program uses regulated prediction markets and independent data verification to establish public probabilities for ...

HT2A receptor inverse agonist advances in clinical development, with phase 2 trial results anticipated in late 2026.

Higher diagnostic accuracy reported for dementia experts vs primary care doctors before disclosure of test results, but not after.

Most obesity drugs do not improve quality of life or heart health, according to a review published online July 8 in The BMJ.

Phase 1/2 DELIVER data demonstrated statistically significant dystrophin expression, functional improvements, and a favorable safety profile with z-rostudirsen.

In response to a rising multistate outbreak of Cyclospora infections, the Centers for Disease Control and Prevention (CDC) has issued a health advisory for clinicians. This summary highlights the ...

At 12 months, adults with insulin-treated diabetes had significant improvements in HbA1c and hospitalizations.

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.